OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

Taipei, Taiwan. June 06, 2025 – OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related  Master Services Agreement (MSA).